Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Krystal Biotech (KRYS) Accumulated Depreciation & Amortization (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Accumulated Depreciation & Amortization for 5 consecutive years, with $31.3 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 42.71% to $31.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.3 million through Dec 2025, up 42.71% year-over-year, with the annual reading at $31.3 million for FY2025, 42.71% up from the prior year.
  • Accumulated Depreciation & Amortization hit $31.3 million in Q4 2025 for Krystal Biotech, up from $29.2 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $31.3 million in Q4 2025 to a low of $2.8 million in Q4 2021.
  • Historically, Accumulated Depreciation & Amortization has averaged $12.9 million across 5 years, with a median of $9.9 million in 2023.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: soared 216.33% in 2023 and later surged 42.71% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $2.8 million in 2021, then skyrocketed by 46.44% to $4.1 million in 2022, then skyrocketed by 216.33% to $12.8 million in 2023, then soared by 70.88% to $21.9 million in 2024, then soared by 42.71% to $31.3 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for KRYS at $31.3 million in Q4 2025, $29.2 million in Q3 2025, and $26.7 million in Q2 2025.